|
Pyroxamide in Treating Patients With Advanced Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Pyroxamide in Treating Patients With Advanced Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Pyroxamide in Treating Patients With Advanced Cancer Clinical research trials and Pyroxamide in Treating Patients With Advanced Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Pyroxamide in Treating Patients With Advanced Cancer. Pyroxamide in Treating Patients With Advanced Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Pyroxamide in Treating Patients With Advanced Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Pyroxamide in Treating Patients With Advanced Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pyroxamide in Treating Patients With Advanced Cancer  Pyroxamide in Treating Patients With Advanced Cancer
Pyroxamide in Treating Patients With Advanced Cancer
For Condition: Eye Cancer,Lymphoma,Leukemia,Multiple Myeloma
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.
Details: OBJECTIVES: I. Determine the maximum tolerated dose of pyroxamide in patients with advanced malignancies. II. Define, qualitatively and quantitatively, the dose-limiting and non-dose-limiting toxic effects of this drug in these patients. III. Describe the pharmacologic behavior of this drug in these patients. PROTOCOL OUTLINE: This is a dose-escalation study. Patients receive pyroxamide IV continuously over 5-7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of pyroxamide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for resolution of adverse events. PROJECTED ACCRUAL: A maximum of 32 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically or cytologically confirmed solid tumor or hematologic malignancy - Disease that has failed standard therapies (e.g., surgery, radiotherapy, endocrine therapy, or chemotherapy) or for which no curative or life- prolonging therapy is available Measurable or clinically evaluable disease - Elevated tumor marker is acceptable for evaluable disease No known carcinomatous meningitis, primary brain tumors, or metastatic brain disease --Prior/Concurrent Therapy-- Biologic therapy: No concurrent bone marrow growth factors Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: - See Disease Characteristics Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior wide-field radiotherapy and recovered - At least 2 weeks since prior limited-field radiotherapy and recovered - Recovered from prior radiotherapy Surgery: See Disease Characteristics Other: No other concurrent antitumor treatment --Patient Characteristics-- Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 125,000/mm3 - Hemoglobin at least 9.0 g/dL Hepatic: - Bilirubin normal - AST no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present) - PT no greater than 1.5 times ULN Renal: Creatinine normal Other: - HIV-positive status allowed - Prior malignancy allowed - No severe physical or emotional illness that would preclude study - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LeonardSaltz, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000069483; NCI-2110,MSKCC-99090
Study Start Date: April 2002
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00042900
Other Multiple Myeloma Studies:
1. Epoetin alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
2. Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
3. UARK 2003-33, Total Therapy III
4. Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
5. Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
Related Studies:
Other Multiple Myeloma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Pyroxamide in Treating Patients With Advanced Cancer
|
|
|
|
|
|
|
|
